DataM Intelligence | competitive Intelligence Spinal Muscular Atrophy treatment is evolving fast, with gene therapy, oral drugs, and next-g ...

We haplotyped 13 Finnish, 10 Swedish, 12 Danish and 2 Norwegian SBMA (spinal and bulbar muscular atrophy, Kennedy disease) families with a total of 45 patients and 7 ;carriers for 17&nbsp ...

For the first time in India, a newborn diagnosed with Spinal Muscular Atrophy (SMA) received pre-symptomatic treatment within days of birth in Kerala, marking a significant milestone in the treatment ...

Dr. Mili Thakur is helping couples in West Michigan and across the country make their dreams a reality with her telehealth reproductive genetics consultation practice, Genome Ally.

In this video, Dr Priya Kadam, Director of Reproductive Genomics at MedGenome, discusses the critical role of genetics in ...

Panelists discuss how spinal muscular atrophy is an autosomal recessive genetic disease affecting motor neurons with 3 ...

Biogen's early-stage spinal muscular atrophy drug salanersen showed safety, motor improvements and 70% reduction in ...

New data from Biogen reveals higher Spinraza doses may enhance motor function in SMA patients. Read more here.

The cumulative data from the Phase 1 study indicate that salanersen has a generally well tolerated safety profile at both the 40 mg and 80 mg doses, with most adverse events (AEs) mild to moderate in ...

"Spinal Muscular Atrophy Pipeline"Spinal Muscular Atrophy companies are Amniotics, Biohaven Pharmaceuticals, Hoffmann-La Roche, Amylon Therapeutics, Voyager Therapeutics, Catalyst Pharmaceuticals ...

Spinal muscular atrophy (SMA) is a severe motor neuron disease caused by mutations in the SMN1 gene, leading to reduced SMN protein levels. Although postnatal treatments like the antisense ...